GlaxoSmithKline and XenoPort, Inc. achieved positive results from a Phase II trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in patients with neuropathic pain associated with post-herpetic neuralgia (PHN), who have had an inadequate response to gabapentin. In this double-blind, two-period cross-over study, 3600 mg/day of GSK1838262 demonstrated a statistically significant improvement over 1200 mg/day of GSK1838262 on the primary endpoint, which was the change from baseline to the end ...